Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
ABBOTT LABORATORIES incurred senior notes of $20,000,000,000 aggregate principal amount with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC at Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30 maturing 2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066.
- Instrument
- senior notes
- Principal
- $20,000,000,000 aggregate principal amount
- Counterparty
- Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC
- Rate
- Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30
- Maturity
- 2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066
- Event
- incurrence
Exact text from the filing
On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC
- Value
- $20,000,000,000 aggregate principal amount
- Effective
- 2026-02-23
Exact text from the filing
The Notes were sold pursuant to a pricing agreement, dated February 23, 2026 (the “Pricing Agreement”), by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein.
View on SEC.gov